The ASCO Post

SBRT Plus Chemoradiotherapy in Locally Advanced NSCLC

A phase II trial assessed the potential benefit of primary lung tumor stereotactic body radiotherapy followed by mediastinal chemoradiotherapy for locally advanced NSCLC.

New Test Could Predict Survival in Early Lung Cancer

The ORACLE test may be capable of predicting lung cancer survival at the point of diagnosis more effectively than currently used clinical risk factors.

ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer

Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer. These findings from the phase III ADRIATIC trial represent the first major progress in the treatment of limited-stage SCLC in nearly 40 years.

TODAY IN ONCOLOGY

Brentuximab Vedotin Plus Lenalidomide/Rituximab in Relapsed/Refractory DLBCL

Study Finds Travel Distance to Lung Cancer Screening Facilities Differs by Race and Ethnicity

Oncolytic Virus Granted Orphan Drug Designation for Pancreatic NETs

Dato-DXd in Advanced/Metastatic NSCLC With Actionable Mutations

A phase II trial demonstrated “encouraging activity” of datopotamab deruxtecan (Dato-DXd) in patients with advanced or metastatic NSCLC with actionable genomic alterations whose disease progressed after targeted therapy and platinum-based chemotherapy.

Toripalimab Plus Chemotherapy for Extensive-Stage Small Cell Lung Cancer

The Chinese phase III EXTENTORCH trial explored whether the addition of toripalimab to first-line chemotherapy with etoposide plus cisplatin or carboplatin improved progression-free survival among patients with extensive-stage small cell lung cancer.

Metformin May Impact Immunotherapy in NSCLC

Metformin may strengthen the effects of immunotherapy and improve recurrence-free survival in patients with lung cancer with overweight or obesity.